Previous studies in PD and Alzheimer’s disease (AD) demonstrated that nilotinib reduces brain DA breakdown as measured by DA metabolites, including homovanillic acid (HVA) [22,23,34], and it inhibits mono-amine oxidase (MAO)-B activity in a dose dependent manner [34]. The gene discussed is MAOB; the disease is Alzheimer disease.